Ovarian Cancer

Explore the complexities of Mother’s Day and clinical trials. Learn how research offers hope and different outcomes for patients facing ovarian cancer.

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

In the last month, I had a revelation about my illness.

FDA approved Lifyorli plus Abraxane, improving survival in platinum-resistant ovarian, fallopian tube and peritoneal cancers.

Keytruda plus weekly paclitaxel improved overall and progression-free survival in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

No matter how hard this is, I still recommend clinical trials. Not as a last resort, but as an important option when weighing treatment choices. I don’t know what choice I’ll make, but I’m thankful I’m still here to have that choice.

FDA approvals, survival gains and equity research led February’s top gynecologic cancer stories, alongside a survivor Q&A on mental health.

Keytruda plus paclitaxel improved overall survival by 18% in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

App-based self-acupressure improved fatigue and quality of life for women with ovarian cancer in a phase 3 trial, with benefits lasting to 24 weeks.

Study finds survival was similar during ovarian cancer trials, but gaps returned after, underscoring need for broader, more inclusive enrollment.

Black patients were underrepresented in ovarian cancer trials and had lower overall survival than White patients in a pooled analysis of 1,903 participants.

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive Keytruda.

FDA OKs Keytruda with paclitaxel for PD-L1 positive, platinum-resistant ovarian, fallopian tube or peritoneal cancers, improving survival and delaying growth.

Relacorilant plus Abraxane improved overall survival by 4.1 months without added toxicity and no biomarker testing in ROSELLA.

Stick your toes in the ocean. Feed the koi. Play make-believe carwash with a toddler. Hold his hand because he asks you to. Be present.

This guide provides an overview of stage 2 uterine (endometrial) cancer, including diagnosis, treatment options, and common side effects. A cancer diagnosis is life-changing, and it is natural to feel

The FDA granted fast track designation to JSKN003 in platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.

Learn what stage 2 ovarian cancer means, how it’s diagnosed, treatment options like surgery and chemotherapy, and key questions to ask your oncologist.

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.

The FDA has accepted a new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.

CURE spoke with Dr. Ryan Kahn of Miami Cancer Institute for Ovarian Cancer Awareness Month.

Women diagnosed with ovarian cancer should consult a fertility specialist immediately, as egg or embryo freezing is most effective before treatment starts.

The FDA has granted fast track designation to stenoparib, an investigational therapy for patients with advanced ovarian cancer.